NEW YORK, April 24, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The global market for OTC medicines and dietary supplements reached $128.8 billion in 2012. This market is expected to reach to $142.7 billion in 2013 and $189.7 billion in 2018, with a compound annual growth rate (CAGR) of 5.9%.
This report provides:
An overview of the global market for OTC drugs and dietary supplements.
Analyses of global market trends, with data from 2012 and 2013, and projections of CAGRs through 2018.
Information about how pharmacies affect the OTC drug market
Updates on the latest merger and acquistion activity
Company profiles of major players in the market
STUDY GOALS AND OBJECTIVES
This BCC Research report analyzes the global trends in OTC drugs and dietary supplements market. OTC medicines have been on the market since the 1970s; however, the late 19th and early 20th century witnessed certain changes and a positive approach globally that encouraged the business of OTC medicines and dietary supplements. The market for OTC medicines around the globe is witnessing new dynamics. This new segment of medicines has encouraged people toward self-care and self-medication on one hand, and on the other hand regulatory agencies are still in a dilemma in regard to the provision of medicines into the hands of people without supervision. The journey of self-medication was initiated as the treatment of common primary health conditions which is now transforming into wellness management. Consumers worldwide in both developed and developing nations are responding to self-care due to its many benefits. However, regulatory bodies, understanding that any medication comes with side effects, are cautious about encouraging self-medication practices. The permutations in drug approvals such as differentiating drugs as pharmacy only and general sales hesitance in approving point-of-sale other than pharmacies show that regulatory authorities are still in the process of finalizing regulatory policies for the OTC drugs.The objective of this study is to assess future prospects and opportunities in OTC drugs and dietary supplementsglobally. The report delves into questions such as: Which countries are establishing potential markets? Is the shift from prescription to nonprescription status still an effective strategy? What strategies current leaders in OTC drugs and dietary supplement manufacturers are adopting? How point of sales and channels of distribution drive sales of OTC drugs and dietary supplements? And what categories of OTC medicines will grow through 2018?
REASONS FOR DOING THE STUDY
Many nations are still in the process of developing strong regulatory policies for OTC drugs and define review process for reclassifying drugs from prescription to nonprescription status. These nations have yet to develop strong safety and quality standards and labeling policies for the OTC drugs. These developments will provide an opportunity to manufacturers and marketers of OTC medicines and dietary supplements to expand organically. The study will engender understanding as to the length and breadth of the market as well as encourage strategical thinking for entering into new potential markets, design marketing strategies and plan on the basis of improving regulatory approach of many nations.
SCOPE OF REPORT
The report covers developed and emerging markets in order to help readers understand:
The current state of the OTC medicines and dietary supplements market and the key markets for its future development.
New regulations that will influence the development of the OTC medicines and dietary supplements market.
Market drivers of and threats to the OTC medicines and dietary supplements industry.
Major regional trends in the global OTC medicines and dietary supplements market.
The competitive thrust of the market.
Executives of pharmaceutical companies that are currently marketing OTC medicines and dietary supplements.
Executives of companies that provide third-party manufacturing and development facilities for OTC medicines and dietary supplements.
Manufacturers of bulk active ingredients and inactive ingredients such as base, resins, pigments and other raw materials for the manufacturing of OTC medicines and dietary supplements.
FMCG companies that intend to enter the OTC medicines and dietary supplements market.
Entrepreneurs, management consultants, and merger and acquisition (M&A) consultants.
Financial institutions, venture capitalists and angel investors.
Manufacturers and exporters of alternate OTC medicines and food supplements.
Government agencies, public health departments and organizations working in regulations and process development of OTC medicines and dietary supplements.
The information and analysis presented in this BCC Research report are based on firsthand information from primary executives, product managers and clinical specialists; background information obtained from various government, business, medical journal and trade magazines; and statistical data from various governmental organizations and trade associations.Key information from published literature was used to conduct interviews with industry participants in order to validate and obtain expert opinions on current and future trends. Interviews were also used to confirm and/or adjust market size and market share estimates as well as to formulate market projections. Data are expressed in 2012 U.S. dollars. The base year was 2012. Historical data are provided for 2011 and forecast data are provided for 2013 and 2018. Historical, base year and forecast data are provided for each market segment and sub-segment. Market shares are provided for each market segment for the base year of 2012.
Chapter- 1: INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE OF REPORT
RELATED BCC RESEARCH REPORTS
BCC RESEARCH ONLINE SERVICES
Chapter- 2: SUMMARY
HIGHLIGHTS OF THE YEAR 2012
TRENDS IN OTC MEDICINES AND DIETARY SUPPLEMENTS THROUGH 2018
FORECAST TRENDS IN OTC MEDICINES BY THERAPEUTIC CLASS THROUGH 2018
Table Summary : GLOBAL MARKET FOR OTC MEDICINES AND DIETARY SUPPLEMENTS THROUGH 2018
Figure Summary : GLOBAL MARKET FOR OTC MEDICINES AND DIETARY SUPPLEMENTS 2011-2018
Chapter- 3: OVERVIEW
RECLASSIFYING PRESCRIPTION MEDICINES TO NONPRESCRIPTION (RX TO OTC)
COMMON ADMINISTRATION METHODS FOR OTC MEDICINES
LEADING THERAPUTIC CLASSIFICATIONS OF OTC MEDICINES
Chapter- 4: GLOBAL MARKETS FOR OTC MEDICINES AND DIETARY SUPPLEMENTS
GLOBAL OTC MEDICINE AND DIETARY SUPPLEMENT MARKET - 2012
GLOBAL MARKET FOR OTC MEDICINES AND DIETARY SUPPLEMENTS, 2013 TO 2018
MARKETS FOR OTC MEDICINES AND DIETARY SUPPLEMENTS BY REGION - 2013 TO 2018
EUROPE'S OTC MEDICINES MARKET
THE U.K. OTC MEDICINES MARKET 2013 THROUGH 2018
GERMANY'S OTC MEDICINES MARKET 2013 THROUGH 2018
FRANCE'S OTC MEDICINES MARKET 2013 THROUGH 2018
POLAND'S OTC MEDICINES MARKET 2013 THROUGH 2018
ASIA-PACIFIC OTC MEDICINES MARKET 2013 THROUGH 2018
BRAZIL, RUSSIA, INDIA AND CHINA (BRIC) - OTC MEDICINES MARKET 2013 THROUGH 2018
BRIC OTC MEDICINES MARKET 2013 THROUGH 2018
INDIA - OTC MEDICINES MARKET
Chapter- 5: GLOBAL SALES OF OTC MEDICINES AND DIETARY SUPPLEMENTS BY SALES CHANNELS
GLOBAL MARKET FORECAST FOR OTC MEDICINES AND DIETARY SUPPLEMENTS BY SALES CHANNELS, THROUGH 2018
Chapter- 6: GLOBAL MARKET FORECAST FOR OTC MEDICINES BY THERUPEUTIC CLASSIFICATION
GLOBAL SALES FORECAST BY THERUPEUTIC CLASSIFICATION FOR OTC MEDICINES
GLOBAL MARKET FORECAST FOR OTC DIETARY SUPPLEMENTS (VMS) 2013 THROUGH 2018
Chapter- 7: OTC MEDICINES AND DIETARY SUPPLEMENT INDUSTRY AND MARKET ANALYSIS
THE PRACTICE OF BUYING OTC MEDICINES
ROLE OF PHARMACY IN OTC MEDICINES
REGULATORY INFLUENCE ON OTC MEDICINE MARKET
KEY STRATEGIC INITIATIVES FOR MARKET PENETRATION AND EXPANSION
DRIVERS AND BARRIERS OF OTC MEDICINE INDUSTRY
STRENGTHS, WEAKNESSES, OPPORTUNITIES AND THREATS (SWOT) ANALYSIS OF THE OTC MEDICINE AND DIETARY SUPPLEMENT INDUSTRY
Chapter- 8: COMPANY PROFILES
ALFRESA PHARMA CORPORATION
ARKOPHARMA PHARMACEUTICAL LABORATORIES (LABORATOIRES PHARMACEUTIQUES)
ASPEN PHARMACARE AUSTRALIA PTY. LTD.
BAUSCH & LOMB
BAYER HEALTHCARE AG
BOEHRINGER INGELHEIM GMBH
CARMA LABORATORIES, INC.
CORDIA HEALTHCARE (CAVENDISH PHARMACEUTICALS)
DAIICHI SANKYO CO., LTD.
FERTIN PHARMA A/S
GABA INTERNATIONAL AG
GEMINI PHARMACEUTICALS, INC.
GENOMMA LAB INTERNATIONAL
HISAMITSU PHARMACEUTICAL CO., INC.
INSIGHT PHARMACEUTICALS LLC
JOHNSON & JOHNSON
KOWA COMPANY, LTD.
LAKE CONSUMER PRODUCTS, INC.
MANX HEALTHCARE LIMITED
MCM KLOSTERFRAU VERTRIEBS GMBH (KLOSTERFRAU HEALTHCARE GROUP)
MCNEIL CONSUMER HEALTHCARE
MERCK CORPORATE HEADQUARTERS
MOCHIDA PHARMACEUTICAL CO., LTD.
NEPENTES SA / NEPENTES PHARMA SP. Z O.O.
NORTHEAST PHARMACEUTICAL GROUP CO. LTD
NOVARTIS INTERNATIONAL AG
PGT HEALTHCARE (DIVISION OF PROCTER & GAMBLE)
PIERRE FABRE PHARMACEUTICALS INC.
PIRAMAL HEALTHCARE LTD
PRESTIGE BRANDS HOLDINGS, INC.
RECKITT BENCKISER PLC.
RECKITT BENCKISER (NORTH AMERICA) INC.
RECORDATI PHARMA GMBH
REVOLYMER (U.K.) LTD
SAGE PRODUCTS LLC
SATO PHARMACEUTICAL CO., LTD.
STADA ARZNEIMITTEL AG
SWISSE WELLNESS PTY LTD.
TAISHO PHARMACEUTICAL HOLDINGS
TAKEDA PHARMACEUTICALS LTD.
TISSO NATURPRODUKTE GMBH
WELLSPRING PHARMACEUTICAL CORPORATION
Contact Clare: firstname.lastname@example.org
Intl: +1 339-368-6001